Tranexamic acid has one of the more unusual career paths in skincare. For decades it was known to surgeons and haematologists as a clotting drug — given to control heavy bleeding. Then dermatologists noticed something curious in patients taking it: their melasma faded. That accidental discovery has turned a humble haemostatic medicine into one of the most talked-about brightening actives in K- and J-beauty, and a genuine third way to tackle pigmentation that works quite differently from vitamin C or niacinamide.
What it is
Tranexamic acid (often shortened to TXA) is a small synthetic molecule — trans-4-(aminomethyl)cyclohexane-1-carboxylic acid — built around a cyclohexane ring. It is a derivative of the amino acid lysine, and that resemblance is the key to how it works. As an antifibrinolytic, it has roughly ten times the clot-stabilising potency of its predecessor, ε-aminocaproic acid, which is why its original and licensed use remains the control of bleeding, from heavy periods to surgical and dental procedures.
How it brightens — via a completely different route
Most pigment-fading actives target the pigment factory directly. Vitamin C and arbutin inhibit the enzyme tyrosinase; niacinamide blocks the hand-off of finished pigment from melanocytes to skin cells. Tranexamic acid works upstream of all that, by interrupting one of the signals that tells melanocytes to switch on in the first place.
The trigger is an enzyme called plasmin. Ultraviolet light activates plasmin in keratinocytes, which in turn releases arachidonic acid and prostaglandins and raises levels of alpha-melanocyte-stimulating hormone (α-MSH) — all of which prod melanocytes into producing more melanin. Because tranexamic acid mimics lysine, it plugs the lysine-binding sites that plasmin needs, dampening this whole cascade. The result is less pigment signalling, rather than a blocked pigment factory.
Because it works on the keratinocyte–melanocyte conversation rather than on tyrosinase, tranexamic acid complements the brighteners you may already use — it is not simply another version of the same thing.
There is a second string to its bow. Melasma is not purely a pigment problem; it has a vascular component, with excess tiny blood vessels feeding the patches. Tranexamic acid reduces plasmin-driven production of vascular endothelial growth factor (VEGF) and endothelin-1, which helps calm that redness and vascularity. It also bears a passing structural resemblance to tyrosine, giving it a modest competitive tyrosinase-inhibiting effect on top.
The J-beauty connection
Japan has a formal regulatory category of "quasi-drug" whitening actives — ingredients with recognised, evidence-backed brightening effects — and tranexamic acid is one of them, classed among the agents that work by interrupting keratinocyte-to-melanocyte signalling. That official standing is a large part of why it features so prominently in Japanese and Korean brightening formulas, and why it has earned a reputation as a serious, science-led active rather than a passing trend.
Oral versus topical: an important distinction
The strongest evidence for tranexamic acid in melasma comes from oral low-dose use, which many dermatologists now regard as a highly effective option for stubborn cases — though it is prescribed off-label and requires medical supervision, because as a clotting medicine it is not suitable for anyone with a history of, or risk factors for, blood clots.
Topical tranexamic acid — the version in your serum, usually at 2–5% — is the safer, accessible route and has shown real benefit in studies. Its limitation is delivery: the molecule is water-loving and does not cross the skin's oily barrier easily, nor linger long enough to reach melanocytes in quantity. This is why well-formulated products often pair it with humectants such as hyaluronic acid to improve penetration, and why in-clinic protocols sometimes deliver it via microneedling. Applied topically at cosmetic strengths, it does not raise blood levels meaningfully, so the clotting concerns of the oral drug do not apply.
How to use it
Topical tranexamic acid is well tolerated and plays nicely with others. It layers comfortably with niacinamide, vitamin C and gentle exfoliating acids, and a sensible brightening routine might combine two complementary mechanisms rather than doubling up on one. As with every pigmentation treatment, the single most important partner is sunscreen: without daily, diligent SPF, melasma will simply return faster than any active can fade it. Expect gradual progress over a couple of months, and treat topical TXA as a steady contributor to a brightening routine rather than a stand-alone cure.
The verdict
Tranexamic acid is a clever, well-credentialled brightening active with a mechanism that genuinely fills a gap left by the tyrosinase-blockers. Topically it is gentle, sensible and a strong team player for melasma and post-inflammatory marks; orally it is powerful but firmly a doctor's decision. For anyone building a considered brightening routine — especially one inspired by the evidence-led J-beauty approach — it is a worthy and distinctive addition.
This article is for general education and is not medical advice. Oral tranexamic acid is a prescription medicine and should only be taken under the supervision of a doctor.
References
Mechanism of Action of Topical Tranexamic Acid in the Treatment of Melasma and Sun-Induced Skin Hyperpigmentation. Cosmetics, 2022, 9(5):108. mdpi.com/2079-9284/9/5/108
Konisky H, et al. Tranexamic acid in melasma: A focused review on drug administration routes. Journal of Cosmetic Dermatology, 2023. onlinelibrary.wiley.com/doi/10.1111/jocd.15589
AlJabr, et al. Tranexamic Acid for Hyperpigmentation Disorders: A Literature Review on Efficacy and Safety in Melasma and PIH. Journal of Cosmetic Dermatology, 2026. onlinelibrary.wiley.com/doi/10.1111/jocd.70692
Ando H, Matsui MS, Ichihashi M. Quasi-drugs developed in Japan for the prevention or treatment of hyperpigmentary disorders. International Journal of Molecular Sciences, 2010. ncbi.nlm.nih.gov/pmc/articles/PMC2920561/
Tranexamic acid. DermNet. dermnetnz.org/topics/tranexamic-acid